Subsequently, proteomic analysis of the CPTAC-Glioma cohort revealed that 71% of PANoRGs (10/14; note: data for AIM2, IRF1, NLRP3, and ZBP1 were not obtained) are more highly expressed in GBM, whereas 14% (2/14, MAP3K7 and NFS1) are expressed at lower levels in GBM tissues than in non-tumor brain tissues (Fig. 2D). This evidence concerns the gene AIM2 and central nervous system cancer.